| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +17,986 | +9.3% | $0.000000 | 212,334 | 13 Feb 2025 | Direct | F1 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +7,378 | +3.5% | $0.000000 | 219,712 | 13 Feb 2025 | Direct | F2 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +6,060 | +2.8% | $0.000000 | 225,772 | 13 Feb 2025 | Direct | F3 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +7,074 | +3.1% | $0.000000 | 232,846 | 13 Feb 2025 | Direct | F4 |
| holding | ABBV | Common Stock, $0.01 par value | 2,601 | 13 Feb 2025 | Profit sharing trust | F5 | |||||
| holding | ABBV | Common Stock, $0.01 par value | 3,873 | 13 Feb 2025 | By spouse in trust | F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Option (Right to Buy) | Award | $0 | +25,000 | $0.000000 | 25,000 | 13 Feb 2025 | Common Stock | 25,000 | $192.86 | Direct | F7 |
| Id | Content |
|---|---|
| F1 | Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| F2 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| F3 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| F4 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| F5 | Balance in AbbVie Savings program as of January 31, 2025. Balance includes shares acquired pursuant to a dividend reinvestment feature. |
| F6 | The reporting person disclaims beneficial ownership of all securities held by her spouse. |
| F7 | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on February 13, 2026, 8,333 on February 13, 2027, and 8,333 on February 13, 2028. |
Due to an administrative error the exercise price for options awarded February 15, 2024 was previously reported as $0 in Table II Column 2, instead of the correct value of $175.28